Biotechnology Remote Clinical-Monitoring Law In Russia.
1. Introduction
Biotechnology Remote Clinical-Monitoring Law in Russia concerns the legal framework governing the use of digital technologies, telecommunications, medical devices, electronic health records, wearable sensors and remote medical supervision in biotechnology research and healthcare.
Remote clinical monitoring allows healthcare professionals, clinical investigators, biotechnology companies and research institutions to monitor patients and clinical-trial participants without requiring their continuous physical presence at a hospital or research centre.
Examples include:
Remote monitoring of patients participating in biotechnology clinical trials.
Monitoring gene-therapy patients through digital health platforms.
Remote monitoring of vaccine clinical-trial participants.
Monitoring patients receiving stem-cell therapies.
Monitoring blood glucose, blood pressure and cardiac activity through connected medical devices.
Remote assessment of adverse events and treatment outcomes.
Electronic collection and verification of clinical-trial data.
Remote supervision of patients receiving personalised biological medicines.
An important legal distinction: Russian law regulates remote patient observation and clinical-trial monitoring through different legal mechanisms. Remote patient observation is expressly addressed by Article 36.2 of Federal Law No. 323-FZ, whereas clinical-trial monitoring is governed by pharmaceutical legislation and Good Clinical Practice requirements.
There is no single comprehensive Russian statute entitled the Remote Clinical-Monitoring Law. Instead, several laws, regulations and technical standards operate together.
2. Constitutional and Legislative Foundation
The principal constitutional provisions include:
Article 41 – Right to health protection and medical assistance.
Article 23 – Protection of privacy.
Article 24 – Restrictions on the collection, storage and use of information concerning private life.
Article 46 – Judicial protection of rights.
These constitutional guarantees are particularly important when biotechnology companies collect patients' genetic information, physiological measurements and medical records remotely.
The principal statutory framework includes:
| Legislation | Legal significance |
|---|---|
| Federal Law No. 323-FZ of 2011 | Healthcare and telemedicine regulation |
| Federal Law No. 61-FZ of 2010 | Circulation of medicinal products and clinical trials |
| Federal Law No. 152-FZ of 2006 | Personal data protection |
| Federal Law No. 242-FZ of 2017 | Introduction of telemedicine-related amendments |
| Federal Law No. 258-FZ of 2020 | Experimental legal regimes for digital innovation |
| Government and Ministry of Health regulations | Operational requirements for telemedicine and clinical research |
These provisions must be interpreted together rather than treating remote monitoring as an independent, unrestricted digital service.
3. Article 36.2 of Federal Law No. 323-FZ: Remote Medical Monitoring
Article 36.2 of the Russian Federal Law on the Fundamentals of Health Protection of Citizens is the central provision governing telemedicine and remote patient observation.
It establishes the legal framework for providing medical assistance through telemedicine technologies.
Important requirements include:
A. Medical supervision
Remote medical observation must be prescribed by the treating physician after an in-person appointment, examination or consultation, subject to applicable statutory exceptions.
B. Medical-device data
Remote observation may rely on patient information recorded through medical devices designed to monitor the human body's condition.
Examples include:
Blood-pressure monitors.
Continuous glucose-monitoring systems.
Cardiac monitoring devices.
Wearable physiological sensors.
Other registered medical monitoring devices.
C. Medical information systems
Information may be processed through:
The Unified State Health Information System (EGISZ).
Regional state health information systems.
Medical information systems.
Other legally recognised information systems.
D. Medical confidentiality
Remote medical monitoring must comply with personal-data legislation and medical-secrecy requirements.
E. Identification and authentication
The law establishes identification and authentication requirements for participants in remote medical interactions.
F. Electronic documentation
Medical documentation relating to telemedicine must be properly recorded, including the use of the healthcare professional's enhanced qualified electronic signature.
These requirements make Article 36.2 particularly important for remote monitoring of patients receiving gene therapy, regenerative medicine and other advanced biotechnology treatments.
Consultant Plus+1
4. Ministry of Health Order No. 193n of 11 April 2025
Effective 1 September 2025
The Ministry of Health adopted Order No. 193n, establishing the current procedure for organising and providing medical assistance using telemedicine technologies.
It replaced the previous Order No. 965n of 30 November 2017.
The new procedure is particularly relevant to biotechnology remote clinical monitoring.
Its important features include:
Remote interaction between healthcare professionals.
Remote interaction between doctors and patients.
Real-time medical consultations.
Asynchronous consultations based on electronic medical records.
Remote medical observation.
Electronic transmission of diagnostic information.
Use of clinical decision-support systems, including qualifying AI-based medical-device software.
The Order recognises that information obtained through remote observation may be used in preparing medical consultations and clinical conclusions.
It also establishes procedures for preparing and transmitting medical information electronically.
The Order is effective until 1 September 2031.
Consultant Plus+1
5. Clinical-Trial Monitoring Under Federal Law No. 61-FZ
Federal Law No. 61-FZ of 12 April 2010, concerning the circulation of medicinal products, provides the principal legislative framework for clinical trials of medicinal products in Russia.
This legislation is important for biotechnology products such as:
Recombinant proteins.
Monoclonal antibodies.
Gene-therapy medicines.
Cell-based medicinal products.
Biological vaccines.
Advanced therapeutic medicinal products.
Clinical-trial monitoring involves checking whether the trial is conducted according to its approved protocol, applicable regulatory requirements and Good Clinical Practice.
The principal participants include:
A. Sponsor
The sponsor organises and finances the clinical trial and is responsible for establishing appropriate monitoring arrangements.
B. Clinical investigator
The investigator supervises the trial participants and ensures that their medical treatment and safety are properly managed.
C. Contract Research Organisation (CRO)
A CRO may perform delegated monitoring and research-management functions.
D. Regulatory authorities
Russian regulatory authorities supervise compliance with applicable clinical-trial requirements.
6. Good Clinical Practice and Remote Monitoring
Russian clinical research must comply with applicable Good Clinical Practice requirements.
The Rules of Good Clinical Practice approved by Ministry of Health Order No. 200n of 1 April 2016 establish important obligations concerning clinical-trial monitoring.
The principal objectives of monitoring are:
Protection of participants' rights and safety.
Verification of clinical-trial data.
Verification of compliance with the approved protocol.
Identification of inaccurate or incomplete records.
Detection of deviations from clinical-trial procedures.
Reporting and management of safety problems.
The sponsor must ensure that clinical-trial monitoring is conducted by appropriately qualified personnel.
Remote monitoring can be particularly useful when the investigator and sponsor are geographically separated.
However, remote monitoring does not automatically eliminate the need for physical inspections.
Remote monitoring versus on-site monitoring
| Issue | Remote monitoring | On-site monitoring |
|---|---|---|
| Data review | Electronic access | Physical access |
| Patient observation | Digital information | Direct examination where appropriate |
| Source-document verification | Restricted by access arrangements | Direct inspection |
| Safety assessment | Remote reporting and review | Direct clinical assessment |
| Research-site inspection | Limited | Physical inspection |
| Regulatory oversight | Required | Required |
The Russian National Standard GOST R ISO 14155-2014 is also relevant to clinical investigations of medical devices.
Its monitoring provisions recognise that, in exceptional circumstances, a sponsor may use remote monitoring without visiting the research centre, provided that the sponsor justifies the approach and establishes appropriate safeguards.
The standard also requires a documented monitoring plan.
asclepius.ru+1
7. Informed Consent and Patient Autonomy
Informed consent is a fundamental legal requirement in biotechnology clinical research.
Remote monitoring must not undermine the patient's right to understand and voluntarily accept participation in a clinical trial.
The consent process should address:
The purpose of remote monitoring.
The types of medical information collected.
The use of wearable medical devices.
Electronic transmission of health information.
Access to clinical records.
The possibility of automated data analysis.
The risks of data breaches.
The procedures for reporting adverse events.
The patient's right to withdraw from research, subject to applicable legal requirements.
For example, a patient participating in a gene-therapy clinical trial may be required to transmit physiological measurements and laboratory results to the research team.
The sponsor and investigator must ensure that the participant understands the monitoring arrangements and relevant privacy implications.
Article 20 of Federal Law No. 323-FZ is particularly relevant to consent to medical intervention.
Article 13 addresses medical confidentiality, including the circumstances in which confidential medical information may be disclosed for scientific research.
8. Personal Data Protection and Genetic Information
Remote biotechnology monitoring involves the processing of particularly sensitive information.
Examples include:
Genetic information.
Genomic sequencing results.
Biomarker information.
Medical histories.
Physiological measurements.
Treatment-response records.
Reproductive health information.
Federal Law No. 152-FZ regulates personal-data processing.
Important legal obligations include:
A. Lawful processing
Personal information must be processed on an appropriate legal basis.
B. Purpose limitation
Information should be collected and used for specified lawful purposes.
C. Data minimisation
Only information necessary for the relevant purpose should be collected.
D. Information security
Organisations must implement appropriate organisational and technical security measures.
E. Cross-border transfers
Where clinical-trial data are transferred outside Russia, the requirements of Article 12 of Federal Law No. 152-FZ must be considered.
F. Data localisation
Article 18(5) establishes requirements concerning the recording, systematisation, accumulation, storage and other specified operations involving personal data of Russian citizens using databases located in Russia, subject to statutory exceptions.
A foreign biotechnology sponsor cannot assume that remote access to Russian patient records is automatically lawful merely because the sponsor has obtained contractual permission from the research institution.
The requirements of medical confidentiality under Article 13 of Federal Law No. 323-FZ must also be respected.
minzdrav.gov.ru+1
9. Regulation of Medical Devices Used for Remote Monitoring
Remote monitoring frequently depends on medical devices and software.
Examples include:
Wearable ECG monitors.
Continuous glucose monitors.
Remote cardiac monitoring systems.
Digital diagnostic devices.
Medical imaging platforms.
AI-supported clinical monitoring software.
Russian medical-device regulation requires attention to the applicable registration and conformity requirements.
The legal framework includes Federal Law No. 323-FZ and the relevant medical-device registration rules.
Where software performs a medical function, its legal classification may depend on its intended purpose and functionality.
For example, a general-purpose fitness application is not automatically a medical device. However, software intended to diagnose, monitor or support medical decisions may fall within medical-device regulation.
A biotechnology company must therefore examine:
Whether the device requires registration.
Whether its intended use is properly documented.
Whether its clinical performance is sufficiently established.
Whether software updates affect its regulatory status.
Whether cybersecurity safeguards are adequate.
Whether the device produces reliable and reproducible measurements.
10. Liability for Remote Clinical-Monitoring Failures
Remote monitoring can create liability when a medical professional, sponsor, CRO or technology provider fails to comply with applicable obligations.
The principal forms of liability include:
A. Medical professional liability
A healthcare professional may face civil, disciplinary or other legally applicable liability for negligent medical supervision.
B. Medical organisation liability
A medical organisation may be responsible for failures in medical documentation, patient supervision or the organisation of medical assistance.
C. Sponsor liability
The sponsor remains responsible for ensuring appropriate clinical-trial oversight, even where monitoring functions have been delegated to a CRO.
D. Data-protection liability
Unlawful processing, disclosure or inadequate protection of personal information may result in regulatory and civil consequences.
E. Product liability
A defective medical monitoring device may create liability under applicable product-safety and civil-law rules.
F. Research misconduct
Falsification of monitoring records, inaccurate reporting of adverse events or deliberate manipulation of trial data can lead to regulatory consequences and potentially other legal proceedings.
11. Important Russian Case Laws and Judicial Decisions
Russian judicial practice concerning remote clinical monitoring is developing. There is an important distinction between decisions directly concerning telemedicine and decisions concerning the broader responsibilities of clinical-trial sponsors.
The following decisions are relevant to the interpretation of this area.
Case 1. Ninth Cassation Court of General Jurisdiction, 6 February 2025
Case No. 8G-12682/2024 (88-819/2025)
Legal issue: Legality of remote medical consultation and correction of treatment.
The dispute concerned a child's medical treatment and a telemedicine consultation between doctors at different medical institutions.
The patient's mother challenged the legality of the consultation and sought compensation for moral harm.
The court examined whether the consultation had been conducted in accordance with the applicable telemedicine rules.
Judicial findings:
Doctor-to-doctor telemedicine consultation was legally permissible.
The consultation was organised by the treating physician.
The medical recommendations were consistent with the available medical records.
The court found no established violation of the child's interests.
The claim challenging the consultation and seeking compensation was rejected.
Legal principle: Remote medical consultation is not unlawful merely because the patient or legal representative does not personally participate in a doctor-to-doctor consultation.
Relevance: This decision is useful when determining the legality of remote supervision and the responsibilities of treating physicians.
ГАРАНТ
Case 2. Russian Supreme Court, 16 May 2022
Case No. 18-КГПР22-28-К4
Legal issue: Medical liability and the use of telemedicine technologies.
This decision concerned a claim for compensation for moral harm arising from allegedly inadequate medical assistance involving diagnostic and therapeutic procedures.
The case is relevant to the judicial examination of medical negligence and the standard of care where telemedicine is involved.
Legal significance:
The use of technology does not remove the medical organisation's responsibility to provide appropriate medical assistance.
Courts must examine the actual medical circumstances, the quality of the treatment and whether the applicable professional obligations were fulfilled.
Relevance: This principle is important when remote clinical monitoring is used to support diagnosis or treatment decisions.
rudn.ru
Case 3. Fourth Cassation Court of General Jurisdiction, 2 June 2022
Case No. 88-17695/2022; underlying Case No. 2-349/2021
Legal issue: Failure to undertake necessary medical examinations and establish a correct diagnosis.
The litigation concerned allegedly inadequate medical care and the failure to take all necessary and available measures to examine a patient.
The case illustrates the importance of adequate diagnostic procedures and medical supervision.
Legal principle: Remote medical technologies cannot be treated as a substitute for necessary examinations where the patient's condition requires direct clinical assessment.
Relevance: Remote monitoring systems must provide a mechanism for escalation to in-person examination when measurements or symptoms indicate a potential medical risk.
rudn.ru
Case 4. Ninth Arbitration Court of Appeal, 17 October 2022
Case No. A40-246516/2019; Appeal No. 09АП-46126/22
Legal issue: Sponsor responsibility and clinical-trial monitoring.
This commercial dispute considered obligations associated with clinical research and the responsibilities of sponsors and contract research organisations.
The relevant clinical-research principles include:
Appropriate selection of investigators and research institutions.
Proper monitoring of clinical trials.
Documented delegation of responsibilities.
Adequate supervision of research activities.
Responsibility for the quality and completeness of clinical-trial data.
Legal principle: Delegating clinical-trial monitoring to a CRO does not automatically transfer the sponsor's ultimate responsibility for the quality and completeness of the trial data.
Relevance: This is particularly important when remote monitoring is outsourced to international CROs or digital clinical-research platforms.
ГАРАНТ
Case-law qualification: These decisions provide relevant judicial guidance, but they should not all be described as direct precedents on wearable-device monitoring or remote source-data verification. No reported Russian judgment specifically establishing a comprehensive doctrine for remote clinical-trial monitoring has been identified in the sources examined.
12. Major Legal Challenges
Russia faces several legal challenges in implementing remote biotechnology monitoring.
| Legal challenge | Main concern |
|---|---|
| Patient identification | Incorrect patient identification |
| Data accuracy | Inaccurate device measurements |
| Cybersecurity | Unauthorised access to health records |
| Clinical responsibility | Unclear allocation of responsibilities |
| AI monitoring | Incorrect automated medical assessments |
| Informed consent | Insufficient disclosure of monitoring practices |
| Cross-border research | International transfer of patient information |
| CRO outsourcing | Sponsor accountability |
| Device malfunction | Inaccurate clinical information |
| Adverse-event reporting | Delayed identification of serious risks |
13. Regulatory Authorities and Their Functions
Several Russian authorities have important responsibilities.
| Authority | Relevant responsibility |
|---|---|
| Ministry of Health | Healthcare and telemedicine regulation |
| Roszdravnadzor | Healthcare supervision and medical-device oversight |
| Roskomnadzor | Personal-data protection supervision |
| Ethics committees | Ethical review of clinical research |
| Ministry of Industry and Trade | Relevant pharmaceutical and industrial policy functions |
| Courts | Civil, administrative and other applicable legal disputes |
14. Practical Example: Remote Monitoring of a Gene-Therapy Clinical Trial
Consider a biotechnology company conducting a gene-therapy clinical trial in Russia.
The trial involves 100 participants who receive an investigational biological treatment.
The company provides participants with connected medical monitoring devices.
Illustrative remote-monitoring structure
Clinical-trial participant
Receives gene therapy and uses monitoring devices
Connected medical devices
Collect physiological measurements and health information
Secure medical information system
Records, transmits and protects monitoring information
Clinical investigator
Reviews clinical information and assesses patient safety
Sponsor and regulatory oversight
Trial monitoring, safety reporting and compliance verification
Suppose one participant develops an abnormal cardiac measurement.
The legal consequences may include:
The monitoring system records the abnormal measurement.
The clinical investigator evaluates the information.
The investigator determines whether an in-person examination is necessary.
Any relevant adverse event is documented.
Serious adverse reactions are reported according to applicable requirements.
The sponsor evaluates whether the event affects the safety of other participants.
Regulatory authorities may investigate suspected non-compliance.
If the monitoring system fails to transmit the information and the patient suffers harm, liability will depend on the actual cause of the failure, the applicable duties of each party and the available evidence.
15. Recommendations for Strengthening Russian Remote Clinical-Monitoring Law
The following reforms could improve legal certainty:
1. Dedicated remote-monitoring legislation
Russia could introduce more detailed statutory provisions specifically addressing remote clinical-trial monitoring.
2. Clear sponsor accountability
Legislation should clarify the division of responsibility between sponsors, CROs, investigators and technology providers.
3. Stronger cybersecurity requirements
Clinical-monitoring platforms should undergo appropriate cybersecurity assessments.
4. Standardised electronic records
Uniform standards should be developed for electronic source documents, audit trails and remote verification.
5. AI accountability
The law should clarify responsibility when AI-based monitoring systems generate incorrect clinical alerts or recommendations.
6. Patient protection
Patients should receive clear information about data collection, remote observation, confidentiality and escalation procedures.
7. Cross-border regulatory cooperation
International biotechnology research requires clearer procedures for lawful access to clinical-trial information and international data transfers.
16. Conclusion
Biotechnology Remote Clinical-Monitoring Law in Russia is based on the interaction of healthcare legislation, pharmaceutical regulation, clinical-trial standards, personal-data protection and medical-device regulation.
Article 36.2 of Federal Law No. 323-FZ establishes the principal framework for remote observation of patients. Ministry of Health Order No. 193n of 2025 provides the current operational telemedicine procedure. Federal Law No. 61-FZ and applicable Good Clinical Practice requirements govern clinical-trial monitoring.
The judicial decisions discussed above demonstrate important principles concerning medical responsibility, the legality of remote consultations, adequate patient examination and sponsor accountability.
However, Russia still needs more detailed legal clarification concerning remote source-data verification, wearable monitoring devices, AI-based safety assessment and international clinical-trial data access.
The central legal principle is that remote clinical monitoring may modernise biotechnology research, but it does not eliminate the obligations to protect patients, maintain reliable clinical evidence, preserve medical confidentiality and ensure regulatory accountability.
17. Important Legal References and Research Sources
Federal Law No. 323-FZ – Article 36.2: Telemedicine technologies.
Ministry of Health Order No. 193n of 11 April 2025.
Russian Good Clinical Practice Rules – Order No. 200n.
GOST R ISO 14155-2014 – Clinical investigation of medical devices.
Federal Law No. 323-FZ – Medical confidentiality, Article 13.
Ninth Cassation Court decision of 6 February 2025.
Ninth Arbitration Court of Appeal decision of 17 October 2022.
Academic research note: For formal legal publication, the current consolidated Russian-language texts of the legislation, applicable EAEU clinical-trial requirements and full court judgments should be checked before relying on individual provisions or case citations.

comments